Caplin Point Laboratories Limited

Caplin Point Laboratories Limited, established in 1990, is a prominent Indian pharmaceutical company specializing in the development, production, marketing, and export of generic formulations and branded products. Headquartered in Chennai, Tamil Nadu, the company operates under the Corporate Identification Number (CIN) L24231TN1990PLC019053. Listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524742 and the National Stock Exchange (NSE) as CAPLIPOINT, Caplin Point has demonstrated significant growth and market presence.

The company offers a diverse product portfolio, including tablets, capsules, injections, ophthalmic solutions, liquid orals, softgel capsules, ointments, creams, gels, and more. With over 4,000 product registrations across more than 36 therapeutic areas, Caplin Point has established a strong foothold in various global markets.

As of March 2026, Caplin Point Laboratories Limited employs approximately 3,966 individuals, reflecting its substantial operational scale. The company's official website, www.caplinpoint.net, provides comprehensive information about its products, services, and corporate initiatives.

Caplin Point Laboratories Limited operates multiple manufacturing facilities across India, each designed to cater to specific market needs and regulatory standards. The primary manufacturing plant, located in Suthukeny, Puducherry, is approved by INVIMA (Colombia) and WHO-GMP, focusing on emerging markets in Latin America and Africa. This facility produces a wide range of dosage forms, including sterile liquids, lyophilized injectables, pre-filled syringes, tablets, capsules, liquid orals, soft gelatin capsules, dry powder for oral suspension, suppositories, ovules, and topicals such as creams, lotions, and ointments.

Another significant facility is Caplin Steriles Limited (CP-IV), which specializes in sterile injectables and ophthalmic products. This plant is approved by the US FDA, EU-GMP, INVIMA, and WHO-GMP, underscoring its compliance with stringent international quality standards.

Caplin Point Laboratories Limited is led by a team of seasoned professionals committed to driving the company's growth and strategic direction. Mr. C.C. Paarthipan serves as the Chairman, bringing nearly three decades of experience in the pharmaceutical industry. His leadership has been instrumental in expanding the company's global footprint, particularly in Latin America and Africa.

Dr. Sridhar Ganesan, the Managing Director and Whole-Time Director, has over 35 years of global leadership experience in the pharmaceutical sector. His expertise spans profit center management, global marketing, and international collaborations, contributing significantly to Caplin Point's rapid growth and market presence.

Caplin Point Laboratories Limited has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's subsidiary, Caplin Steriles Limited, has received multiple approvals from the US FDA, including for Labetalol Hydrochloride Injection USP in September 2021 and Desmopressin Acetate Injection USP in February 2026. These approvals highlight Caplin Point's commitment to meeting the stringent regulatory requirements of these markets.

In the European Union, Caplin Point's manufacturing facilities are certified under EU-GMP, ensuring compliance with European quality standards. The company's products are also approved by regulatory bodies in other regions, such as ANVISA in Brazil, INVIMA in Colombia, and COFEPRIS in Mexico, facilitating access to various international markets.

Caplin Point Laboratories Limited has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's manufacturing facility in Puducherry is approved by INVIMA (Colombia) and WHO-GMP, enabling access to these regions. Additionally, Caplin Point's subsidiary, Caplin Steriles USA Inc., operates as a sales and marketing arm in the U.S. market, focusing on high-quality injectables and ophthalmic products.

Caplin Point Laboratories Limited has adopted a diversified geographic strategy, establishing a strong presence in both regulated and emerging markets. The company's focus on Latin America, Africa, and Southeast Asia allows it to tap into high-growth regions with increasing healthcare needs. By obtaining approvals from regulatory bodies such as WHO-GMP and INVIMA, Caplin Point mitigates concentration risk and enhances its global footprint.

Caplin Point Laboratories Limited's subsidiary, Caplin Steriles Limited, has achieved significant milestones with the US FDA. In September 2021, it received final approval for Labetalol Hydrochloride Injection USP, a generic therapeutic equivalent of TRANDATE Injection. In February 2026, Caplin Steriles Limited secured final approval for Desmopressin Acetate Injection USP, a generic version of DDAVP Injection. These approvals underscore Caplin Point's commitment to meeting the stringent standards of the US FDA.

Caplin Point Laboratories Limited's manufacturing facilities are certified under WHO-GMP and EU-GMP, ensuring compliance with international quality standards. The company's facility in Puducherry is approved by WHO-GMP, facilitating access to emerging markets in Africa and Latin America. Additionally, Caplin Steriles Limited's plant is approved by EU-GMP, enabling entry into the European market.

Caplin Point Laboratories Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facilities comply with CDSCO standards, ensuring the production of high-quality pharmaceutical products. State drug controller approvals and export No Objection Certificates (NOCs) further facilitate the company's operations and international trade.

As of March 2026, Caplin Point Laboratories Limited has not reported any Form 483 observations, warning letters, or import alerts from regulatory bodies such as the US FDA. The company's subsidiaries, including Caplin Steriles Limited, have received approvals for products like Labetalol Hydrochloride Injection USP and Desmopressin Acetate Injection USP, indicating a positive regulatory standing.

Caplin Point Laboratories Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. Its focus on generic formulations and branded products positions it against other Indian pharmaceutical exporters and global generics manufacturers. The company's strategic presence in emerging markets, coupled with its regulatory approvals, provides a competitive edge in these regions.

Caplin Point Laboratories Limited distinguishes itself through its diversified product portfolio, encompassing over 4,000 product registrations across more than 36 therapeutic areas. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, EU-GMP, INVIMA, and WHO-GMP, ensuring compliance with global quality standards. Additionally, Caplin Point's strategic focus on emerging markets in Latin America, Africa, and Southeast Asia allows it to address the healthcare needs of underserved populations.

Caplin Point Laboratories Limited's current strategic direction emphasizes the development and manufacturing of generic formulations and branded products, with a particular focus on injectables and ophthalmic products. The company's recent approvals from the US FDA for products like Labetalol Hydrochloride Injection USP and Desmopressin Acetate Injection USP reflect its commitment to expanding its presence in regulated markets. Looking ahead, Caplin Point aims to leverage its manufacturing capabilities and regulatory approvals to further penetrate global markets and address the evolving healthcare needs of diverse populations.

Caplin Point Laboratories Limited has demonstrated a strong track record in the pharmaceutical industry, with a diverse product portfolio and a global presence. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, EU-GMP, INVIMA, and WHO-GMP, indicating a high level of compliance with global quality standards. Caplin Point's strategic focus on emerging markets in Latin America, Africa, and Southeast Asia, coupled with its recent regulatory approvals, underscores its reliability as a supplier capable of meeting